Neuspera Medical, Inc. is committed to developing implantable medical device technology that will improve the lives of patients battling chronic illness. With the first intended indication for use as Urinary Urgency Incontinence (UUI), the platform technology is ultimately designed to deliver targeted bioelectronic medicine for a variety of conditions. Neuspera’s minimally-invasive implants with external wearable transmitters offer the possibility for therapies to reach deeper, harder to access anatomical locations in the body.
Location: United States, California, San Jose
Employees: 11-50
Total raised: $140M
Founded date: 2013
Investors 3
Funding Rounds 4
| Date | Series | Amount | Investors |
| 15.07.2024 | Series D | $23M | - |
| 20.07.2021 | Series C | $65M | Treo Ventu... |
| 20.02.2019 | Series B | $26M | - |
| 24.01.2018 | Series B | $26M | - |
Mentions in press and media 18
| Date | Title | Description |
| 12.09.2024 | Neuspera Medical, Inc. Welcomes Bunty Banerjee as Its First Chief Operating Officer | - |
| 26.07.2024 | Neuspera Medical, Inc. Reaches Significant Milestone: Final Patient has Completed Primary Endpoint Visit in the SANS-UUI Pivotal Clinical Trial | - |
| 15.07.2024 | Neuspera Medical Raises $23 Million in Series D Financing | - |
| 15.07.2024 | Neuspera Medical Raises $23M in Series D Financing | Neuspera Medical, a San Jose, CA-based neuromodulation company, raised $23M in Series D funding. The round was led by Vertex Ventures HC and Treo Ventures with participation from Action Potential Venture Capital, Windham Venture Partners, O... |
| 21.07.2021 | Neuspera Medical Closes $65M Series C Equity Financing | Neuspera Medical Inc., a San Jose, Calif.-based clinical stage, private venture capital backed neuromodulation company, closed a $65m series C equity financing. The round was co-led by Vertex Ventures HC and Treo Ventures with participation... |
| 20.07.2021 | Neuspera Medical Announces Close of a $65M Series C Equity Financing | |
| 20.07.2021 | Neuspera Medical scores $65M for nerve-stimulating implant to treat overactive bladder | Neuspera Medical’s miniaturized neuromodulation device may take up mere millimeters of space, but it’s making an outsized impact on the field of medical technology. The device is implanted into the body to stimulate nerves linked to chronic... |
| 20.07.2021 | Neuspera Medical scores $65M for nerve-stimulating implant to treat overactive bladder | Neuspera Medical’s miniaturized neuromodulation device may take up mere millimeters of space, but it’s making an outsized impact on the field of medical technology. RELATED: Bioelectronics startup Neuspera nets $26M in two-tranche series B ... |
| 20.07.2021 | Neuspera Medical Announces Close of a $65M Series C Equity Financing | SAN JOSE, Calif., July 20, 2021 /PRNewswire/ -- Neuspera Medical Inc., a clinical stage, private venture capital backed neuromodulation company, today announced the closing of the company's $65 million series C equity financing. The Series ... |
| 22.02.2019 | Bioelectronics startup Neuspera nets $26M in two-tranche series B | Neuspera Medical has raised a new total of $26 million in equity financing, following the closing of the second tranche of its series B round, to help fund clinical testing programs for its neuromodulation implants. Sponsored by Agilent Tec... |
Show more